To celebrate🗺️World Lab Day🧪on April 23, we’re kicking off our mini-series “It All Starts with Curiosity” today. We’ll take you inside the world of LOEWE research—you’re warmly invited to join us. Feel free to share your answers in the comments section.✍🏽More ➡️ www.linkedin.com/posts/proloe...
📣 ESTRO 2026 Pre-Meeting Webinars
Get ready for #ESTRO26 with two online pre-meeting webinars ahead of the congress in Stockholm (15–19 May 2026).
Cases will be discussed — we can’t wait to engage with you!
🔗 Info & registration: bit.ly/4pAM9PH
#PMCwebinars #ESTRO26
The #NeuroRNA team really enjoyed attending the #CancerNeuroscience meeting organised by the #EACR this week in #Bilbao. Josune Alonso and Ane Rubio presented their projects in #RNA misprocessing in #GBM @biogipuzkoa.bsky.social @helloeacr.bsky.social
Congrats to Ethan Ludmir and Chad Tang for their publication selected for recognition as part of @mdanderson.bsky.social Excellence in Science Award. #radonc #endcancer
ascopubs.org/doi/10.1200/...
Interested in #reirradiation heading to the first full day of #ESTRO25? Why not follow our
🔹Reirradiation Journey🔹
through the conference programme! Find it in the programme filter options - or below #radonc #medphys
✨We're thrilled to be taking part in #ESTRO25 in Vienna!
EORTC researchers will be presenting cutting-edge findings in #RadiationOncology, a cornerstone of our scientific strategy.
Find out more: www.eortc.org/blog/2025/05...
@estroradiotherapy.bsky.social #CancerResearch
What a start , @mguckenberger.bsky.social with an emotional and inspiring talk at the opening Ceremony, Pascal Uffer delivered more than a talk ; if cancer were a start up. #ESTRO25 #radonc #radiotherapy
The phase III NRG/RTOG 0920 trial explored adding cetuximab to postoperative radiotherapy (RT) in 577 patients with resected intermediate-risk SCCHN.
📊 Key Findings @ascocancer.bsky.social #JCO
#Onco404 #Cancer #Kanser #Oncology #HeadAndNeckCancer #RadiationTherapy #Cetuximab #ClinicalTrials #HPV
In the KEYNOTE-689 trial, neoadjuvant pembrolizumab delivered a game-changing:
✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92)
✅ Median EFS: 51.8 months vs. 30.4 months
No clear benefit seen in the hypopharynx subgroup
#HNSCC #Radonc #Immunotherapy #CancerResearch
Treatment of Pleural Mesothelioma: ASCO Guideline Update
https://buff.ly/3WrRMUm
The ASCO guidelines for pleural #mesothelioma (PM) provide evidence-based recommendations for physicians on managing this condition. #LungCancer
bevacizumab, a VEGF inhibitor, in patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
https://buff.ly/40qpx9W
Nivolumab Improves DFS in High-Risk Head & Neck SCC
The Phase 3 NIVOPOSTOP trial (680 patients) showed that adding nivolumab to standard post-op CRT significantly improved DFS in resected LA-SCCHN with high relapse risk. A trend toward better OS was observed, pending final analysis.
Our latest study, "Pulmonary Stereotactic Body Radiotherapy (SBRT) of Oligometastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC): A Multicenter Retrospective Study", is now available in the @ijrobp.bsky.social
www.redjournal.org/article/S036...
In Greenland, as we speak.
Todas is HCC day!
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...
The RACE-GB trial results are here! FIRST randomized controlled trial investigating radiotherapy (RT) in gallbladder cancer.
In a cohort of 135 patients the addition of RT after 4 cycles of chemotherapy (compared to observation) extended overall survival (OS) from 4 months to 10 months.@RadOnc
#RadOnc starter pack loading! Please let me know if you would like to be added.
go.bsky.app/TbynCkm
#oncsky #bcsm #gyncsm #hncsm
Radiation Oncology is characterized by rapid innovation
Dissemination & implementation are important aspects to bring this progress to our cancer patients in daily practice
Well written review by Erin Gillespie and colleagues 👇
www.redjournal.org/article/S036...
Great list , please add me
Great , please add me to the list
Please add me #radonc
Hi , I’d like to be included